Repaglinide 1 MG tablet 90S
Ended Awarded Last action
- Contract number
- SPE2DR26FL090
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,718
Award facts
- Contract value 100% obligated
- $13,718.27 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $13,718.27 to AmerisourceBergen Drug Corp for the supply of Repaglinide 1 mg tablets (90-count units) with a firm fixed-price structure. The award, issued on January 30, 2026, is scheduled for ultimate completion by February 2, 2026, with performance taking place at the contractor's Conshohocken, Pennsylvania location. This contract represents a non-set-aside, competitively awarded transaction issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide.
AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., operates as a major pharmaceutical distributor and critical federal medical procurement vendor, particularly serving military and veteran healthcare systems. The company's portfolio of federal contract awards demonstrates extensive capabilities in supplying brand-name and generic medications across multiple therapeutic domains, including diabetes treatments, neurological medications, pain management pharmaceuticals, and specialized medical supplies. The delivery order for Repaglinide, an oral diabetes medication, exemplifies the company's role in fulfilling essential pharmaceutical needs for the Defense Health Agency and other government healthcare systems through flexible, competitively awarded contract mechanisms.
Quick answers
Who was awarded contract SPE2DR26FL090?
SPE2DR26FL090 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 30, 2026.
How much is contract SPE2DR26FL090 worth?
The government has obligated $13,718 on SPE2DR26FL090.
Is contract SPE2DR26FL090 an order under another contract?
Yes. SPE2DR26FL090 is a delivery order under SPE2DR25D1104, an indefinite delivery contract.
Was contract SPE2DR26FL090 competed?
The extent of competition for SPE2DR26FL090 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award